Duligotuzumab. Human anti-EGFR/anti-HER3 MAb, colorectal cancer therapy, head and neck cancer therapy

Cole, P.

doi:10.1358/dof.2015.040.03.2312450

Cited by 6 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… Two-in-one antibody Duligotuzumab is a two-in-one (DAF) phage-derived humanized antibody. It binds to EGFR and HER3, resulting in the inhibition of the downstream signaling pathways of HER-family [ 53 ]. Deregulated EGFR- and HER3-dependent signaling is involved in the pathogenesis of human cancers such as head and neck and colorectal cancers.…”

Section: Bsabs Blocking Signaling Pathwaysmentioning

confidence: 99%

Bispecific antibodies and their applications

et al. 2015

View full text Add to dashboard Cite

Bispecific antibodies (BsAbs) recognize two different epitopes. This dual specificity opens up a wide range of applications, including redirecting T cells to tumor cells, blocking two different signaling pathways simultaneously, dual targeting of different disease mediators, and delivering payloads to targeted sites. The approval of catumaxomab (anti-EpCAM and anti-CD3) and blinatumomab (anti-CD19 and anti-CD3) has become a major milestone in the development of bsAbs. Currently, more than 60 different bsAb formats exist, some of them making their way into the clinical pipeline. This review summarizes diverse formats of bsAbs and their clinical applications and sheds light on strategies to optimize the design of bsAbs.

show abstract

Section: Bsabs Blocking Signaling Pathwaysmentioning

confidence: 99%

Bispecific antibodies and their applications

et al. 2015

View full text Add to dashboard Cite

show abstract

“…The PI3K/AKT/mTOR pivot, a mechanism for targeted resistance, is started by both IGF-IR and HER3. MM-141 interacts with HER3 and IGF-IR, impeding the resistance mechanism [43]. MM-141 is now being studied in stage I in hepatocellular cancer patients.…”

Section: Hsa Body Bispecific Antibodiesmentioning

confidence: 99%

Clinical Application of Therapeutic Bispecific Antibodies

Belachew

2023

BJSTR

View full text Add to dashboard Cite

Bispecific antibodies (BsAbs) have been developed, with one antigen-binding site coordinated against the CD3 receptor (which activates cytotoxic T lymphocytes) and the other against specific antigens found on cancer cells (CD19, CD20, CD33, CD123, HER2, epithelial cell adhesion molecule [EpCAM], BCMA, CEA, and others). Bispecific antibodies (BsAbs) are unique immunological constructs that frequently recognize two distinct target antigens from multiple proteins. In the 1980s, the first advanced BsAb archetypes were developed. Using compound formation methods or quadroma innovation, comprising somatic hybridization of two antibody-secreting hybridoma cells, the first BsAbs were produced. In any event, the immunogenicity or complexity of their manufacture placed limitations on these approaches. Concentrating on two or more approved pathways can increase restorative viability and address the attractive and regular use of BsAbs in IBD. Furthermore, the extraordinary ability of BsAbs to act as bridging molecules between various therapeutic targets offers new ways to maximize their use. Soundly planned BsAbs employ a variety of therapeutic strategies, including the direct targeting of particular immune cell subsets, the colocalization and cross-connection of cell surface receptors to activate novel signaling, or the rerouting of the immune system to attack pathogenic cell subsets. Two BsAbs have so far been approved for usage in the US (blinatumomab; Amgen) and Europe (catumaxomab; Trion Pharma). It became possible to obtain many iterations of potential Ab derivatives for use in treatment thanks to the development of novel procedures for BsAb aging. This article aims to provide an overview of the therapeutic benefits of bispecific antibodies.

show abstract

“…Duligotuzumab is an antibody that blocks ligand binding to EGFR and HER3 [ 54 ]. Duligotuzumab is demonstrated to induce ADCC using in vitro models and able to bind to Fc receptors [ 55 ].…”

Section: The Application Of Antibodies Nanobodies and Bi-specific Antibodies In Crc Immunotherapymentioning

confidence: 99%

Recent Advances on Immune Targeted Therapy of Colorectal Cancer Using bi-Specific Antibodies and Therapeutic Vaccines

et al. 2021

View full text Add to dashboard Cite

Colorectal cancer (CRC) is a universal heterogeneous disease that is characterized by genetic and epigenetic alterations. Immunotherapy using monoclonal antibodies (mAb) and cancer vaccines are substitute strategies for CRC treatment. When cancer immunotherapy is combined with chemotherapy, surgery, and radiotherapy, the CRC treatment would become excessively efficient. One of the compelling immunotherapy approaches to increase the efficiency of CRC therapy is the deployment of therapeutic mAbs, nanobodies, bi-specific antibodies and cancer vaccines, which improve clinical outcomes in patients. Also, among the possible therapeutic approaches for CRC patients, gene vaccines in combination with antibodies are recently introduced as a new perspective. Here, we aimed to present the current progress in CRC immunotherapy, especially using Bi-specific antibodies and dendritic cells mRNA vaccines. For this aim, all data were extracted from Google Scholar, PubMed, Scopus, and Elsevier, using keywords cancer vaccines; CRC immunotherapy and CRC mRNA vaccines. About 97 articles were selected and investigated completely based on the latest developments and novelties on bi-specific antibodies, mRNA vaccines, nanobodies, and MGD007.

show abstract

Duligotuzumab. Human anti-EGFR/anti-HER3 MAb, colorectal cancer therapy, head and neck cancer therapy

Cited by 6 publications

References 0 publications

Bispecific antibodies and their applications

Bispecific antibodies and their applications

Clinical Application of Therapeutic Bispecific Antibodies

Recent Advances on Immune Targeted Therapy of Colorectal Cancer Using bi-Specific Antibodies and Therapeutic Vaccines

Contact Info

Product

Resources

About